← SynDRA
MASITINIB
SynDRA canonical compound SYN0028185 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Primary target(s) | PDGFRB |
| Mechanism of action | PDGFR inhibitor |
| Indication | mastocytoma |
| Disease area | dermatology |
All known targets
- KIT
- PDGFRA
- PDGFRB
- FGFR3
- LYN
- SRC
Mechanisms of action (all sources)
- KIT INHIBITOR
- SRC inhibitor
- PDGFR inhibitor
- FGFR3 INHIBITOR
- Fibroblast growth factor receptor 3 inhibitor
- Stem cell growth factor receptor inhibitor
- PDGFRB INHIBITOR
- Platelet-derived growth factor receptor inhibitor
- PDGFRA INHIBITOR
- PDGFR tyrosine kinase receptor inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- Kinavet
- AB1010
- Masatinib
- Masitinib (AB1010)
- Masivet
- AB 1010
- UNII-M59NC4E26P
- Masitinib [INN]
- M59NC4E26P
- 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide
- CHEMBL1908391
- CHEBI:63450
- Masitinib (INN)
- N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
- Q-201339
- C28H30N6OS
- N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
- masican
- Masiviera
- 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
- MFCD09954132
- 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide
- N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide
- 4-((4-Methylpiperazin-1-yl)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide
- Kinavet CA-1
- masitinib methanesulfonate
- Mastinib
- 4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDE
- G65
- MASITINIB [MI]
- MASITINIB [MART.]
- MASITINIB [WHO-DD]
- MLS006010167
- Masican (proposed trade name)
- SCHEMBL717239
- GTPL5656
- EX-A080
- DTXSID001000207
Look up MASITINIB in the interactive SynDRA portal →